HealthLynked (HLYK) AI Stock Analysis

• Market Cap: $10.40M
• Dividend Yield: N/A
• Average Volume (3M): 2.50K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.58
• Revenue Growth: -28.51%
• EPS Growth: 38.80%
• Country: US
• Employees: 20
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 2,866,104
• 10 Day Avg. Volume: 3,502
• 30 Day Avg. Volume: 2,501
• PEG Ratio: >-0.01
• Price to Book (P/B): -1.93
• Price to Sales (P/S): 2.00
• P/FCF Ratio: -1.72
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 4.88
• Enterprise Value/Gross Profit: 4.99
• Enterprise Value/Ebitda: -5.53
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $1.50 ▲(2.74% Upside)

The overall stock score reflects significant financial challenges, with declining revenues and negative equity being the most critical issues. While technical indicators show some neutral to slightly positive signals, the company's valuation remains unattractive due to its unprofitability. The recent corporate events, including strategic leadership changes, provide a positive outlook for potential future improvements.

Positive Factors

Leadership Changes

The appointment of a new COO with extensive leadership experience is expected to enhance strategic initiatives and governance, supporting the company's national expansion and potential Nasdaq listing.

Board Expansion

The expansion of the Board with experts in insurance and healthcare risk management strengthens governance and aligns with strategic goals to improve healthcare outcomes.

Product and Market Strategy

HealthLynked's focus on digital health solutions aligns with growing demand, potentially driving long-term revenue growth through improved patient engagement and healthcare delivery.

Negative Factors

Declining Revenues

Significant revenue contraction indicates challenges in market positioning and product adoption, potentially impacting long-term financial stability.

Negative Equity

Negative equity suggests financial instability and high leverage, posing risks to the company's solvency and ability to finance future growth.

Negative Cash Flow

Persistent negative cash flow indicates reliance on external financing, limiting financial flexibility and potentially hindering long-term operational sustainability.

HealthLynked Business Overview & Revenue Model

Company Description

HealthLynked (HLYK) is a healthcare technology company focused on creating a patient-centric platform that enhances the delivery and management of healthcare services. The company operates primarily in the health information technology sector, providing a suite of solutions aimed at improving patient engagement, accessibility of health records, and facilitating communication between patients and healthcare providers. Core products include a network that enables patients to manage their medical history and connect with healthcare professionals, as well as tools for healthcare providers to streamline operations and improve patient care.

How the Company Makes Money

HealthLynked generates revenue through various channels, including subscription fees from healthcare providers who utilize its platform for managing patient data and communication. The company also earns money from transaction fees associated with services offered within its network, such as telehealth consultations and appointment scheduling. Additionally, partnerships with healthcare organizations and payers can lead to revenue-sharing arrangements that contribute to its earnings. By focusing on enhancing the efficiency of healthcare delivery and patient engagement, HealthLynked capitalizes on the growing demand for digital health solutions.

HealthLynked Financial Statement Overview

Summary

HealthLynked faces significant financial challenges, with declining revenues, high net losses, and negative equity. The company's reliance on external financing and persistent negative cash flows indicate financial distress. Urgent corrective measures are needed to stabilize the company's finances and improve its long-term viability.

Income Statement

The income statement shows declining revenues from $9,197,992 in 2021 to $3,008,361 in 2024, indicating significant revenue contraction. Gross profit margins remained relatively high, but the company experienced substantial net losses, increasing from -$1,012,203 in 2023 to -$6,131,479 in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges and negative earnings before interest and taxes.

Balance Sheet

The balance sheet reveals a negative stockholders' equity of -$3,129,209 in 2024, down from $804,730 in 2023, highlighting financial instability. The debt-to-equity ratio is effectively unmeasurable due to negative equity, suggesting high leverage. The equity ratio is negative, indicating liabilities exceed assets, signaling potential insolvency risks.

Cash Flow

Cash flow analysis shows consistently negative free cash flow, with -$3,494,122 in 2024. Operating cash flow is negative, indicating the company is not generating sufficient cash from operations to cover its expenses. There is a slight improvement in financing cash flow, suggesting reliance on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.37M	3.01M	5.72M	5.86M	9.20M	6.13M
Gross Profit	2.32M	2.91M	2.35M	5.40M	6.18M	4.97M
EBITDA	-2.10M	-4.36M	-2.75M	-7.05M	-9.85M	-4.73M
Net Income	-3.83M	-6.13M	-1.01M	-8.82M	-10.41M	-6.15M
Balance Sheet
Total Assets	1.76M	2.22M	4.28M	4.58M	10.69M	8.03M
Cash, Cash Equivalents and Short-Term Investments	10.91K	76.24K	247.22K	61.89K	3.29M	162.18K
Total Debt	6.08M	997.85K	1.97M	1.28M	978.19K	3.04M
Total Liabilities	7.20M	5.35M	3.48M	4.27M	3.49M	6.68M
Stockholders Equity	-5.43M	-3.13M	804.73K	314.45K	7.20M	1.35M
Cash Flow
Free Cash Flow	-1.59M	-3.50M	-4.15M	-4.39M	-3.79M	-2.14M
Operating Cash Flow	-1.59M	-3.49M	-4.14M	-4.36M	-3.77M	-2.12M
Investing Cash Flow	425.00K	422.40K	3.51M	-544.75K	-341.36K	1.81M
Financing Cash Flow	1.17M	2.90M	824.09K	1.68M	7.24M	356.80K

HealthLynked Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.46
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HLYK, the sentiment is Positive. The current price of 1.46 is below the 20-day moving average (MA) of 1.92, below the 50-day MA of 1.67, and below the 200-day MA of 2.18, indicating a bullish trend. The MACD of 0.28 indicates Negative momentum. The RSI at 82.76 is Negative, neither overbought nor oversold. The STOCH value of 82.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HLYK.

HealthLynked Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

HealthLynked Corporate Events

HealthLynked Appoints New COO to Boost Strategy

On December 8, 2025, HealthLynked Corp. appointed Duncan McGillivray as Chief Operating Officer, bringing over 30 years of leadership experience in healthcare, technology, and capital markets. His appointment is expected to enhance the company’s strategic initiatives, particularly in capital project financing. Additionally, HealthLynked expanded its Board of Directors by appointing Chris G. Pulos and Jason Bishara, effective December 1, 2025. These appointments aim to strengthen the company’s governance and support its national expansion and potential Nasdaq listing. Pulos and Bishara bring extensive expertise in insurance, healthcare risk management, and financial services, aligning with HealthLynked’s strategy to improve healthcare outcomes through AI-powered solutions.

The most recent analyst rating on (HLYK) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on HealthLynked stock, see the HLYK Stock Forecast page.